In trading on Friday, shares of the Proshares Short High Yield ETF (SJB) entered into oversold territory, changing hands as low as $28.49 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In the case of Proshares Short High Yield, the RSI reading has hit 29.0 — by comparison, the RSI reading for the S&P 500 is currently 65.8. A bullish investor could look at SJB's 29.0 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), SJB's low point in its 52 week range is $28.49 per share, with $34.00 as the 52 week high point — that compares with a last trade of $28.49. Proshares Short High Yield shares are currently trading off about 0.1% on the day.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
Netflix: 3 Key Reasons Investors Should Avoid Its High-Priced Stock
The streaming media giant faces much stiffer competition later this year and is very richly-valued.
Boeing Resumes Slide After Ethiopia Crash Probe Finds Lion Air 'Similarities'
Boeing shares extend declines Monday after investigators in Ethiopia said tjeir probe into last week's deadly cash of the planemaker's 737 MAX 8 jet found "clear similarities" to the October crash of a Lion Air plane that killed 189 people.
Marriott Sees $11 Billion in Shareholder Returns Under 3-Year Business Plan
Marriott International will look to return as much as $11 billion to shareholders over the next three years under a new business plan that includes nearly 300,000 new rooms, the company said Monday ahead of its annual investor presentation in New York.
Dermira Shares Rocket After Successful Phase II Eczema Treatment Study
Dermira shares doubled Monday after the group said its new eczema treatment passed a key study in adult patients with moderate-to-severe atopic dermatitis.